Menu

Researchers Develop a Drug Against the Common Cold

In an in vitro study, the compound completely blocked the replication of rhinoviruses.

May 15, 2018
Catherine Offord

ISTOCK, DR_MICROBEResearchers have developed a compound that blocks the replication of rhinoviruses, the pathogens behind most cases of the common cold. The in vitro study, published yesterday (May 14) in Nature Chemistry, could provide the first step to developing a treatment for a condition that affects the average adult two to three times a year.

“The common cold is an inconvenience for most of us, but can cause serious complications in people with conditions like asthma and [chronic obstructive pulmonary disease],” study coauthor Ed Tate of Imperial College London says in a statement. “A drug like this could be extremely beneficial if given early in infection.”

Despite being so widespread, the common cold has consistently eluded effective medical treatment, both because of the vast number of viruses that cause it—more than 150 strains of rhinovirus infect humans—and because these pathogens are particularly fast-evolving.

Instead of trying to target the viruses themselves, a team led by researchers at Imperial focused its sights on a human enzyme that the viruses hijack to assemble their protein coats after invading cells. Blocking this enzyme with a small-molecule inhibitor, the team found, completely prevented the protein coat from being formed, and halted viral replication without killing cells.

“Because the inhibitor targets proteins that are common to most types of rhinovirus, it would likely have a broad range of activity,” Peter Barlow, an immunologist and spokesperson for the British Society for Immunology who was not involved in the work, tells Newsweek. “While this study was conducted entirely in vitro . . . it shows great promise in terms of eventually developing a drug treatment to combat the effects of this virus in patients.”

Speaking to The Guardian, study coauthor Roberto Solari of Imperial emphasizes that much more research is needed for this to become a reality. “We haven’t done any animal studies, and we obviously haven’t done any studies in humans, so I can’t tell you formally what the animal toxicity of this compound is,” he says. “There is a still a long way before this becomes a medicine.”

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.